New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
New research advances sustainable biotechnology: recreating poisonous plant compounds for medicine, a two-step fermentation that removes up to 99% of off-putting smells, and hybrid plants that cut carbon footprints by 62%.
Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.
Cynata raised $1.5 million through a placement at $0.25 a share ahead of Phase 3 osteoarthritis and Phase 2 aGvHD trial readouts due in May and June 2026. Its aGvHD study has completed the 100-day primary evaluation period for all 65 participants.
A longitudinal study of 460,000 teenagers found adolescent cannabis use was linked to higher risks of later bipolar, psychotic, anxiety and depression diagnoses. Separate research and expert guidance say THC effects, especially long term, still need more study.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
China’s cross-border biotech outlicensing hit US$60 billion in the first quarter of 2026. AbbVie’s up to $745 million Haisco pain deal highlights multinationals’ rising interest in Chinese drug assets.
Phase 3 PSMAddition showed that adding 177Lu-PSMA-617 to ADT plus an ARPI improved radiographic progression-free survival in PSMA-positive mHSPC. Health-related quality of life and pain were largely maintained.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07777432 |
Triple Combination vs. Breastfeeding (Tetanalgesia) for Neonatal Pain Relief |
COMPLETED | NA |
| NCT07776860 |
The Effect of Bubble Machine and Cartoon on Pain and Fear |
COMPLETED | NA |
| NCT07775547 |
Acupressure in Pediatric K-wire Removal |
ACTIVE_NOT_RECRUITING | NA |
| NCT07773259 |
CODEPAD-III (Collaborative Outcomes of DEpression and Pain Associated With Delivery-III) |
NOT_YET_RECRUITING | NA |
| NCT07772583 |
THE EFFECT OF MUSİC THERAPY IN HEMODİALYSİS PATİENTS |
COMPLETED | NA |
| NCT07770529 |
iPad for Post Operative Pain After Tonsillectomy |
TERMINATED | NA |
| NCT07769775 |
The Effect of Multisensory Stimulation During Venipuncture on Pain, Anxiety, and Fear in Children |
SUSPENDED | NA |
| NCT07769385 |
Robotic and Aquarium Fish for Reducing Pain, Fear, and Anxiety in Children |
ENROLLING_BY_INVITATION | NA |
| NCT07767643 |
Personalized Music for Anxiety During Cataract Surgery |
COMPLETED | NA |
| NCT07764731 |
The Effects of Kinesio Tapeing on Facial Swelling Following Bimaxillary Orthognathic Surgery. |
COMPLETED | NA |
